HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation.  Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  HER3 binds neuregulins NRG1 and NRG2, but lacks an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation.  However, heterodimerization with other EGF receptor family members, which have kinase activity, leads to the activation of pathways.  Amplification or overexpression of this gene has been reported in several cancers, including lung, prostate, bladder, and breast tumors.  HER3 is also genetically linked to type 1 diabetes and lethal congenital contracture syndrome-2 (LCCS2). 

HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation.  Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  HER3 binds neuregulins NRG1 and NRG2, but lacks an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation.  However, heterodimerization with other EGF receptor family members, which have kinase activity, leads to the activation of pathways.  Amplification or overexpression of this gene has been reported in several cancers, including lung, prostate, bladder, and breast tumors.  HER3 is also genetically linked to type 1 diabetes and lethal congenital contracture syndrome-2 (LCCS2). 

 

Product Details

 

Gene Symbol: HER3; ERBB3; LCCS2; ErbB-3; c-erbB3; MDA-BF-1; p180-ErbB3; p45-sErbB3; p85-sErbB3

 

NCBI Gene ID: 2065 (human)

 

Uniprot Entry: P21860 (human)

 

Construct Details: Full length human HER3 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles.

 

Vector Type: pLTC (lentiviral expression vector containing a heterologous CMV promoter, see the vector map above)

 

Formulation: Supplied with 10 μg of endotoxin-free plasmid DNA at 200 ng/μl in sterile TE buffer (pH8.0)

 

Gene Insert Size: 4029 (bp)

 

Gene Insert Sequence:  

ATGAGGGCGAACGACGCTCTGCAGGTGCTGGGCTTGCTTTTCAGCCTGGCCCGGGGCTCCGAGGTGGGCAACTCTCAGGC

AGTGTGTCCTGGGACTCTGAATGGCCTGAGTGTGACCGGCGATGCTGAGAACCAATACCAGACACTGTACAAGCTCTACG

AGAGGTGTGAGGTGGTGATGGGGAACCTTGAGATTGTGCTCACGGGACACAATGCCGACCTCTCCTTCCTGCAGTGGATT

CGAGAAGTGACAGGCTATGTCCTCGTGGCCATGAATGAATTCTCTACTCTACCATTGCCCAACCTCCGCGTGGTGCGAGG

GACCCAGGTCTACGATGGGAAGTTTGCCATCTTCGTCATGTTGAACTATAACACCAACTCCAGCCACGCTCTGCGCCAGC

TCCGCTTGACTCAGCTCACCGAGATTCTGTCAGGGGGTGTTTATATTGAGAAGAACGATAAGCTTTGTCACATGGACACA

ATTGACTGGAGGGACATCGTGAGGGACCGAGATGCTGAGATAGTGGTGAAGGACAATGGCAGAAGCTGTCCCCCCTGTCA

TGAGGTTTGCAAGGGGCGATGCTGGGGTCCTGGATCAGAAGACTGCCAGACATTGACCAAGACCATCTGTGCTCCTCAGT

GTAATGGTCACTGCTTTGGGCCCAACCCCAACCAGTGCTGCCATGATGAGTGTGCCGGGGGCTGCTCAGGCCCTCAGGAC 

ACAGACTGCTTTGCCTGCCGGCACTTCAATGACAGTGGAGCCTGTGTACCTCGCTGTCCACAGCCTCTTGTCTACAACAA

GCTAACTTTCCAGCTGGAACCCAATCCCCACACCAAGTATCAGTATGGAGGAGTTTGTGTAGCCAGCTGTCCCCATAACT

TTGTGGTGGATCAAACATCCTGTGTCAGGGCCTGTCCTCCTGACAAGATGGAAGTAGATAAAAATGGGCTCAAGATGTGT

GAGCCTTGTGGGGGACTATGTCCCAAAGCCTGTGAGGGAACAGGCTCTGGGAGCCGCTTCCAGACTGTGGACTCGAGCAA

CATTGATGGATTTGTGAACTGCACCAAGATCCTGGGCAACCTGGACTTTCTGATCACCGGCCTCAATGGAGACCCCTGGC

ACAAGATCCCTGCCCTGGACCCAGAGAAGCTCAATGTCTTCCGGACAGTACGGGAGATCACAGGTTACCTGAACATCCAG

TCCTGGCCGCCCCACATGCACAACTTCAGTGTTTTTTCCAATTTGACAACCATTGGAGGCAGAAGCCTCTACAACCGGGG

CTTCTCATTGTTGATCATGAAGAACTTGAATGTCACATCTCTGGGCTTCCGATCCCTGAAGGAAATTAGTGCTGGGCGTA 

TCTATATAAGTGCCAATAGGCAGCTCTGCTACCACCACTCTTTGAACTGGACCAAGGTGCTTCGGGGGCCTACGGAAGAG

CGACTAGACATCAAGCATAATCGGCCGCGCAGAGACTGCGTGGCAGAGGGCAAAGTGTGTGACCCACTGTGCTCCTCTGG

GGGATGCTGGGGCCCAGGCCCTGGTCAGTGCTTGTCCTGTCGAAATTATAGCCGAGGAGGTGTCTGTGTGACCCACTGCA

ACTTTCTGAATGGGGAGCCTCGAGAATTTGCCCATGAGGCCGAATGCTTCTCCTGCCACCCGGAATGCCAACCCATGGAG

GGCACTGCCACATGCAATGGCTCGGGCTCTGATACTTGTGCTCAATGTGCCCATTTTCGAGATGGGCCCCACTGTGTGAG

CAGCTGCCCCCATGGAGTCCTAGGTGCCAAGGGCCCAATCTACAAGTACCCAGATGTTCAGAATGAATGTCGGCCCTGCC

ATGAGAACTGCACCCAGGGGTGTAAAGGACCAGAGCTTCAAGACTGTTTAGGACAAACACTGGTGCTGATCGGCAAAACC

CATCTGACAATGGCTTTGACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGGGCGGCACTTTTCTCTACTGGCG

TGGGCGCCGGATTCAGAATAAAAGGGCTATGAGGCGATACTTGGAACGGGGTGAGAGCATAGAGCCTCTGGACCCCAGTG 

AGAAGGCTAACAAAGTCTTGGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGGTGTCTTT

GGAACTGTGCACAAAGGAGTGTGGATCCCTGAGGGTGAATCAATCAAGATTCCAGTCTGCATTAAAGTCATTGAGGACAA

GAGTGGACGGCAGAGTTTTCAAGCTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATGCCCACATTGTAAGGC

TGCTGGGACTATGCCCAGGGTCATCTCTGCAGCTTGTCACTCAATATTTGCCTCTGGGTTCTCTGCTGGATCATGTGAGA

CAACACCGGGGGGCACTGGGGCCACAGCTGCTGCTCAACTGGGGAGTACAAATTGCCAAGGGAATGTACTACCTTGAGGA

ACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACTCAAGTCACCCAGTCAGGTTCAGGTGGCAGATTTTG

GTGTGGCTGACCTGCTGCCTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAAGACTCCAATTAAGTGGATGGCCCTT

GAGAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAGCTATGGTGTGACAGTTTGGGAGTTGATGACCTT

CGGGGCAGAGCCCTATGCAGGGCTACGATTGGCTGAAGTACCAGACCTGCTAGAGAAGGGGGAGCGGTTGGCACAGCCCC

AGATCTGCACAATTGATGTCTACATGGTGATGGTCAAGTGTTGGATGATTGATGAGAACATTCGCCCAACCTTTAAAGAA

CTAGCCAATGAGTTCACCAGGATGGCCCGAGACCCACCACGGTATCTGGTCATAAAGAGAGAGAGTGGGCCTGGAATAGC

CCCTGGGCCAGAGCCCCATGGTCTGACAAACAAGAAGCTAGAGGAAGTAGAGCTGGAGCCAGAACTAGACCTAGACCTAG

ACTTGGAAGCAGAGGAGGACAACCTGGCAACCACCACACTGGGCTCCGCCCTCAGCCTACCAGTTGGAACACTTAATCGG

CCACGTGGGAGCCAGAGCCTTTTAAGTCCATCATCTGGATACATGCCCATGAACCAGGGTAATCTTGGGGAGTCTTGCCA

GGAGTCTGCAGTTTCTGGGAGCAGTGAACGGTGCCCCCGTCCAGTCTCTCTACACCCAATGCCACGGGGATGCCTGGCAT

CAGAGTCATCAGAGGGGCATGTAACAGGCTCTGAGGCTGAGCTCCAGGAGAAAGTGTCAATGTGTAGGAGCCGGAGCAGG

AGCCGGAGCCCACGGCCACGCGGAGATAGCGCCTACCATTCCCAGCGCCACAGTCTGCTGACTCCTGTTACCCCACTCTC

CCCACCCGGGTTAGAGGAAGAGGATGTCAACGGTTATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCCTCCCGGG

AAGGCACCCTTTCTTCAGTGGGTCTCAGTTCTGTCCTGGGTACTGAAGAAGAAGATGAAGATGAGGAGTATGAATACATG

AACCGGAGGAGAAGGCACAGTCCACCTCATCCCCCTAGGCCAAGTTCCCTTGAGGAGCTGGGTTATGAGTACATGGATGT

GGGGTCAGACCTCAGTGCCTCTCTGGGCAGCACACAGAGTTGCCCACTCCACCCTGTACCCATCATGCCCACTGCAGGCA

CAACTCCAGATGAAGACTATGAATATATGAATCGGCAACGAGATGGAGGTGGTCCTGGGGGTGATTATGCAGCCATGGGG

GCCTGCCCAGCATCTGAGCAAGGGTATGAAGAGATGAGAGCTTTTCAGGGGCCTGGACATCAGGCCCCCCATGTCCATTA

TGCCCGCCTAAAAACTCTACGTAGCTTAGAGGCTACAGACTCTGCCTTTGATAACCCTGATTACTGGCATAGCAGGCTTT

TCCCCAAGGCTAATGCCCAGAGAACGTAA

 

Primers: Gene insert coding sequence confirmed by following primers:

(a) forward (or 5'-end) primer: 5’-CAAATGGGCGGTAGGCGTG-3’;

(b) reverse (or 3'-end) primer: 5’-CGGGAAGCAATAGCATGATA-3’

 

Note: The sequence may vary due to the naturally occurring variants or mutations, such as single nucleotide polymorphism, or the artifact during PCR amplification.  High fidelity PCR systems should always be used. 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C.  Upon receipt, centrifuge the vial briefly before opening.  Store at –20°C for long-term storage and the product is stable for 6 months. 

 

 

Avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMAN. NOT RESELLABLE OR TRANSFERABLE

 

Your use of this product constitutes acceptance of the Terms & Conditions from G&P Biosciences.

 

 

References

 

1.  J. Biol. Chem. 269: 14303-14306, 1994. 

2.  Science 297: 1330-1333, 2002.

3.  Science 316: 1039-1043, 2007.

4.  Proc. Nat. Acad. Sci. 86: 9193-9197, 1989.

5.  Nature Genet. 40: 1399-1401, 2008.

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here. LTP0261-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.